1875 related articles for article (PubMed ID: 28768320)
1. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
4. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Packer M
Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
[TBL] [Abstract][Full Text] [Related]
13. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
14. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
15. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
16. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
Scheen AJ
Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin decreases myocardial cytoplasmic Na
Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
[TBL] [Abstract][Full Text] [Related]
20. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]